Paper Details

  1. Home
  2. Paper Details

A placebo-controlled trial of paroxetine in the treatment of major depression.

Author: GlaudinV, SmithW T

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Paroxetine, a selective serotonin reuptake inhibitor, showed greater improvement than placebo in treating moderate to severe major depression, but the differences were not statistically significant. However, it was more effective in patients with long-term depression and resulted in a significant reduction in suicidal ideation.
Paper Details　
Original Abstract of the Article :
Paroxetine is a phenylpiperidine compound that selectively inhibits neuronal serotonin uptake in man. In this study, the efficacy of paroxetine was compared with that of placebo in the treatment of 66 outpatients with the diagnosis of moderate-to-severe major depression. The research was a 6-week, p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/1531822

データ提供：米国国立医学図書館（NLM）

A placebo-controlled trial of paroxetine in the treatment of major depression

The field of [Mental health] is continuously searching for effective and safe treatments for [Major depressive disorder]. This study investigates the efficacy of [Paroxetine], a selective serotonin reuptake inhibitor (SSRI), in treating [Moderate-to-severe major depression] compared to [Placebo]. The researchers conducted a double-blind, placebo-controlled trial to assess the effectiveness of this medication. The findings provide valuable insights into the potential benefits and limitations of [Paroxetine] in managing [Major depressive disorder].

Effectiveness of Paroxetine in Depression Treatment

The study found that [Paroxetine] was associated with a greater improvement in [Depression symptoms] compared to [Placebo], but the differences were not statistically significant. However, [Paroxetine] demonstrated significantly greater improvement in patients with [Long-standing depression (more than 1 year)]. The study also revealed a significant reduction in [Suicidal ideation] among patients receiving [Paroxetine] compared to [Placebo]. These findings suggest that [Paroxetine] may be particularly beneficial for patients with [Chronic depression] and those experiencing [Suicidal thoughts].

Navigating the Desert of Depression

This research provides valuable information for [Patients suffering from depression] and [Healthcare professionals] involved in their care. It highlights the importance of [Considering different treatment options] and discussing potential benefits and risks with a healthcare professional. The study emphasizes the need for [Personalized medicine] and the importance of [Continued research] to further understand the effectiveness of various treatments for [Depression].

Dr. Camel's Conclusion

The desert of [Depression] can feel vast and overwhelming. This research provides a glimmer of hope, highlighting the potential benefits of [Paroxetine] for those struggling with [Chronic depression] and [Suicidal ideation]. It reminds us that [Finding the right path for mental health] often involves a journey of exploration and collaboration with a healthcare professional.

Date :
  1. Date Completed 1992-04-08
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

1531822

DOI: Digital Object Identifier

1531822

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.